- Home
- ACON vs VRAX Comparison
ACON vs VRAX Comparison
Compare ACON & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACON
- VRAX
- Stock Information
- Founded
- ACON 2008
- VRAX 2013
- Country
- ACON United States
- VRAX United Kingdom
- Employees
- ACON N/A
- VRAX N/A
- Industry
- ACON Retail: Computer Software & Peripheral Equipment
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ACON Technology
- VRAX Health Care
- Exchange
- ACON Nasdaq
- VRAX Nasdaq
- Market Cap
- ACON 4.2M
- VRAX 4.7M
- IPO Year
- ACON 2022
- VRAX 2022
- Fundamental
- Price
- ACON $7.28
- VRAX $0.81
- Analyst Decision
- ACON Buy
- VRAX Strong Buy
- Analyst Count
- ACON 2
- VRAX 1
- Target Price
- ACON $481.00
- VRAX $3.00
- AVG Volume (30 Days)
- ACON 15.5K
- VRAX 37.2K
- Earning Date
- ACON 08-13-2025
- VRAX 02-05-2025
- Dividend Yield
- ACON N/A
- VRAX N/A
- EPS Growth
- ACON N/A
- VRAX N/A
- EPS
- ACON N/A
- VRAX N/A
- Revenue
- ACON $54,601.00
- VRAX $84,872.00
- Revenue This Year
- ACON $212.31
- VRAX $5,169.18
- Revenue Next Year
- ACON $92.86
- VRAX $66.97
- P/E Ratio
- ACON N/A
- VRAX N/A
- Revenue Growth
- ACON N/A
- VRAX 7.03
- 52 Week Low
- ACON $6.20
- VRAX $0.75
- 52 Week High
- ACON $3,499.51
- VRAX $9.00
- Technical
- Relative Strength Index (RSI)
- ACON 42.96
- VRAX 31.75
- Support Level
- ACON $6.79
- VRAX $0.75
- Resistance Level
- ACON $7.29
- VRAX $0.85
- Average True Range (ATR)
- ACON 0.37
- VRAX 0.07
- MACD
- ACON 0.31
- VRAX -0.01
- Stochastic Oscillator
- ACON 45.79
- VRAX 6.57
About ACON Aclarion Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.